Financial Survey: Shineco (NASDAQ:SISI) & Lyell Immunopharma (NASDAQ:LYEL)

Shineco (NASDAQ:SISI) and Lyell Immunopharma (NASDAQ:LYEL) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, institutional ownership, profitability, dividends and earnings.

Volatility and Risk

Shineco has a beta of -1.33, meaning that its stock price is 233% less volatile than the S&P 500. Comparatively, Lyell Immunopharma has a beta of -0.14, meaning that its stock price is 114% less volatile than the S&P 500.

Profitability

This table compares Shineco and Lyell Immunopharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Shineco	-380.55%	-79.89%	-33.01%
Lyell Immunopharma	-762,355.56%	-90.52%	-70.22%

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Shineco and Lyell Immunopharma, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shineco	1	0	0	0	1.00
Lyell Immunopharma	1	0	2	0	2.33

Lyell Immunopharma has a consensus price target of $39.50, suggesting a potential upside of 86.94%. Given Lyell Immunopharma’s stronger consensus rating and higher possible upside, analysts plainly believe Lyell Immunopharma is more favorable than Shineco.

Institutional and Insider Ownership

4.1% of Shineco shares are held by institutional investors. Comparatively, 66.1% of Lyell Immunopharma shares are held by institutional investors. 0.0% of Shineco shares are held by insiders. Comparatively, 22.3% of Lyell Immunopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Shineco and Lyell Immunopharma”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shineco	$9.60 million	0.01	-$22.45 million	($204.00)	0.00
Lyell Immunopharma	$40,000.00	12,313.51	-$274.45 million	($16.30)	-1.30

Shineco has higher revenue and earnings than Lyell Immunopharma. Lyell Immunopharma is trading at a lower price-to-earnings ratio than Shineco, indicating that it is currently the more affordable of the two stocks.

Summary

Lyell Immunopharma beats Shineco on 8 of the 14 factors compared between the two stocks.

About Shineco

Shineco, Inc., through its subsidiaries, processes and distributes agricultural produce. It also engages in the growing and cultivation of mulberry trees and silkworm cocoons; distribution of fruit business; and processing and distribution of silk and silk fabrics, as well as other by-products. The company was incorporated in 1997 and is headquartered in Beijing, the People's Republic of China.

About Lyell Immunopharma

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.